The U.S. healthcare system has already saved an estimated $23.6 billion from biosimilar use [1]. Yet for all that money redirected, for all the blockbuster patent cliffs navigated and the manufacturing feats achieved, the biosimilar supply chain remains one of the most fragile, legally contested, and strategically underestimated structures in modern medicine.
This is not about biology alone. Every bottle of adalimumab biosimilar that reaches a patient with rheumatoid arthritis passed through a gauntlet: a living cell line that can never produce an exact copy, a cold chain that tolerates almost no error, a patent estate engineered by lawyers to last decades, and a reimbursement system that sometimes prefers an expensive original product to a cheaper copy. Understanding how that gauntlet works — and how to navigate it faster than your competitors — is what separates companies that capture biosimilar markets from those that merely enter them.
This piece covers that gauntlet in full. It draws on manufacturing science, patent law, supply chain logistics, and real-world case data to give pharmaceutical executives, supply chain leaders, legal strategists, and investors the actionable intelligence they need to compete in the biosimilar decade now underway.
Part One: What You’re Actually Dealing With
Biosimilars Are Not Generics — and Your Supply Chain Strategy Has to Reflect That
The comparison between biosimilars and generic small-molecule drugs is common, intuitive, and wrong in almost every practical respect.
A generic drug like metformin is a small molecule. It contains roughly 20 to 100 atoms, has a molecular mass under 1 kilodalton, and can be synthesized through a defined chemical process that produces an identical product every time [2]. When a patent expires on metformin, a manufacturer can copy its structure exactly, run bioequivalence studies, and put a product on pharmacy shelves that is, at the molecular level, identical to the original [3].
Biologics — the reference products that biosimilars shadow — are something else entirely. A monoclonal antibody like adalimumab (Humira) contains roughly 20,000 atoms and a molecular mass approaching 150 kilodaltons [2]. Its three-dimensional shape is not incidental to its function; it is its function. That shape, and the post-translational modifications (PTMs) that govern it — glycosylation patterns, phosphorylation, disulfide bridge formation, oxidation states — emerge from the living cell system used to produce it [4]. Change the cell line, the culture pH, the nutrient concentrations, or the purification method, and you change the product. Not in ways that necessarily matter clinically, but in ways that must be analytically proven not to matter.
This means a biosimilar manufacturer cannot copy a reference product. They can only produce something that is ‘highly similar’ to it — a phrase with regulatory weight but inherent ambiguity [5]. The FDA and EMA both require extensive comparability exercises to prove that any differences from the reference product are not clinically meaningful [6]. That process takes years and costs hundreds of millions of dollars even before the first patient is enrolled in a clinical study.
For a supply chain strategist, this distinction carries immediate operational consequences. You are not managing a commodity. You are managing a biological system producing a complex protein that must be kept within tight temperature bands, characterized by increasingly sophisticated analytical methods, and manufactured under conditions that require regulatory pre-approval before any change is made. Every link in that chain is more expensive, more fragile, and more legally constrained than its small-molecule equivalent.
The Numbers Behind the Opportunity
The global biosimilars market was valued at approximately $34.43 billion in 2024 [7]. Depending on the analytical source, it is forecast to reach somewhere between $175.99 billion and $357.50 billion by 2034, with compound annual growth rates ranging from 17.78% to 24.9% [7][8][9]. These projections are wide, which itself reflects the supply chain truth discussed throughout this article: biosimilar markets are genuinely difficult to forecast.
What is not uncertain is the pressure driving that growth. Humira’s U.S. exclusivity ended in 2023. Stelara (ustekinumab), Keytruda (pembrolizumab), and Eylea (aflibercept) face patent cliffs in the mid-2020s that will collectively expose tens of billions in annual revenue to biosimilar competition [10]. The U.S. market alone is expected to lead global biosimilar adoption from 2025 to 2035 — not because the U.S. regulatory environment is the most favorable (it is not), but because American biologic prices are the highest on earth, making the savings potential proportionally largest.
The economic case for biosimilars is documented and substantial. In therapeutic areas with mature biosimilar competition, cost reductions of 20–30% for rheumatoid arthritis biologics and 15–25% for oncology biologics have been observed [11]. Norway saw a 70% price reduction in reference biologic prices following biosimilar entry; Germany saw roughly 20% [11]. These figures represent real savings in tight healthcare budgets, not projections.
But — and this is the strategic tension that governs everything else in this article — aggressive price competition can destroy the economics that justify biosimilar investment in the first place. When prices erode to 80–85% below the reference product list price, as happened with multiple adalimumab biosimilars, manufacturers with higher cost structures simply cannot sustain participation. A market that produces only three or four viable manufacturers for a given biologic is a fragile one. The same dynamics that produce short-term savings can produce medium-term supply shortages. <blockquote> “The U.S. healthcare system has realized an estimated $23.6 billion in savings from biosimilar use, yet current trajectory suggests savings could reach $180 billion over the next five years if adoption barriers are systematically addressed.” — IQVIA Institute for Human Data Science [12] </blockquote>
Part Two: Manufacturing — Where Complexity Is Baked In
Living Systems, Irreducible Variability, and What That Means for Operations
Every biosimilar begins in a bioreactor full of living cells. The most common are Chinese Hamster Ovary (CHO) cells, though Human Embryonic Kidney 293 (HEK293) cells and others are used depending on the product [13]. These cells have been genetically engineered to produce the target protein, but they are still cells — metabolically complex, sensitive to culture conditions, and prone to variability that chemical synthesis simply does not have.
The key variable is post-translational modification. After a protein is synthesized from its gene template, the cell attaches sugar chains (glycosylation), makes chemical modifications to specific amino acids (phosphorylation, oxidation), and folds the whole structure into its functional three-dimensional shape [4]. These modifications are not genetically encoded — they are a product of the cellular environment. Change the dissolved oxygen concentration in the bioreactor by a few percent, adjust the glutamine concentration in the culture medium, or shift the pH by 0.2 units, and the glycosylation profile of the product changes [4][13]. That change may be analytically detectable but clinically irrelevant, or it may not be — which is exactly the point the regulatory comparability exercise is designed to resolve.
This means that biosimilar manufacturers must develop proprietary cell lines and manufacturing processes that consistently produce a product within the similarity space of the reference biologic [13]. There is no template to follow. The originator’s manufacturing process is their most protected trade secret, and the biosimilar developer must independently discover a process that arrives at a similar destination by a different route [4].
The analytical technology required to characterize these differences has advanced dramatically. Techniques like mass spectrometry, nuclear magnetic resonance spectroscopy, and capillary electrophoresis can now detect structural differences that were invisible twenty years ago [14]. This is both a scientific achievement and a regulatory expectation: the more the field can measure, the more regulators require to be measured and justified.
Newer biological modalities raise the manufacturing bar further still. Bispecific antibodies that bind two different targets simultaneously, fusion proteins combining antibody fragments with other functional domains, and cell and gene therapies represent manufacturing challenges that dwarf conventional monoclonal antibodies [15]. Their complexity makes scaling from clinical-trial batches to commercial manufacturing volumes extraordinarily difficult. The failure rate is high, the specialized expertise is scarce, and the infrastructure requirements are expensive. This is part of why CDMOs (Contract Development and Manufacturing Organizations) have become so central to the biosimilar ecosystem — a topic covered in depth later.
Raw Material Sourcing: The Hidden Vulnerability
The fragility of biosimilar manufacturing does not begin in the bioreactor. It begins months or years earlier, with raw material procurement.
A single biologic manufacturing process may draw on inputs from over 60 different suppliers [16]. Cell culture media, the nutrient-rich liquid that keeps cells alive and productive, is especially critical and especially variable. The quality and composition of these media directly determines cellular productivity, product quality, and the consistency of post-translational modifications across batches [17]. Minor changes in raw material quality — a batch of glutamine with slightly different purity, a trace metal contaminant in a culture supplement — can shift glycosylation profiles or reduce yield [18].
Historically, many biologics relied on bovine serum to provide growth factors. Serum is highly variable between batches and carries the theoretical risk of introducing adventitious agents — viruses, prions — that could contaminate the product [18]. The industry has substantially shifted toward serum-free, chemically defined media over the past decade, which reduces biological contamination risk and improves batch-to-batch consistency. But chemically defined media are not simple: they may contain dozens of components whose interactions are not fully understood, and identifying which components are critical quality attributes requires extensive development work.
The global sourcing of pharmaceutical raw materials introduces additional vulnerabilities. Many key inputs come from suppliers in China, India, Brazil, and Israel [19]. This geographic concentration creates exposure to trade policy changes, export restrictions, customs delays, and quality-control variability across regulatory environments. The COVID-19 pandemic made these vulnerabilities viscerally real: supply chains that had been optimized for cost and efficiency were unprepared for simultaneous disruption across multiple sourcing geographies [20].
Qualifying a new raw material supplier takes up to 24 months, and procurement lead times for established suppliers commonly run 16–24 weeks [16]. These numbers are not negotiable — they reflect the regulatory requirement to validate each material for use in a GMP-compliant process. This means that a supply disruption at a raw material supplier cannot be fixed quickly. By the time an alternative supplier is qualified and their material is validated in the manufacturing process, the damage — batch cancellations, delayed regulatory filings, missed supply commitments — has already occurred.
The operational implication is direct: biosimilar manufacturers need to maintain approved supplier alternatives for their most critical raw materials before they need them. This requires investment in relationship management, supplier qualification programs, and inventory buffering that adds cost to every unit produced. Companies that treat raw material sourcing as a procurement function rather than a supply chain risk management function pay for it eventually.
Cold Chain: Infrastructure as Competitive Moat
Most biologics, including biosimilars, require continuous refrigeration at 2°C to 8°C throughout their supply chain [21]. Some — including mRNA-based products and emerging cell and gene therapies — require ultra-low temperatures of -70°C or below [21]. Neither range tolerates deviation.
The consequences of a cold chain excursion for a biologic are not the same as for a small molecule. A tablet stored at 30°C for an hour might lose some potency. A monoclonal antibody stored at 30°C for an hour may aggregate — forming protein clumps that trigger immune responses in patients [21]. This transforms cold chain integrity from a logistics concern into a patient safety issue.
What this requires operationally is well understood: validated cold chain packaging, qualified temperature monitoring devices, trained personnel at every handoff point, real-time temperature tracking, and documented protocols for handling excursions [22]. Good Distribution Practice (GDP) regulations in both the U.S. and EU mandate these requirements explicitly. U.S. regulations under 21 CFR Part 211.150 require that manufacturers establish stability data and excursion allowances — defined parameters within which brief temperature deviations are acceptable — and that any deviation beyond those limits triggers a quality assessment [22].
The infrastructure investment required to do this at scale is substantial. IoT-enabled containers that transmit real-time temperature, humidity, and GPS location data during transit are now commercially available and increasingly expected [23]. Advanced insulated packaging using vacuum panels extends the time a shipment can withstand ambient temperature exposure. Warehousing at the required temperatures requires specialized HVAC systems, backup power, and continuous monitoring systems. None of this is cheap.
But here is the strategic point: cold chain capability is a genuine competitive differentiator. Companies that have built robust cold chain infrastructure — qualified warehouse networks, carrier relationships, monitoring systems, and documented processes — can handle a broader geographic distribution footprint, respond faster to market opportunities in different regions, and absorb supply chain shocks without product loss. Companies that treat cold chain as a cost to be minimized discover its importance only after a product recall.
For biosimilar manufacturers targeting global markets, the geographic variation in cold chain infrastructure is also a market access factor. A biosimilar might receive regulatory approval in a developing market and still fail to reach patients because the local distribution infrastructure cannot maintain the required temperature range. This creates ethical obligations alongside commercial ones.
Part Three: The Legal Labyrinth — Patents, Dances, and Thickets
How Patent Thickets Actually Work — and Why They Last So Long
When a pharmaceutical company develops a new biologic, the core composition-of-matter patent — covering the molecule itself — provides perhaps 20 years of exclusivity from the date of filing [24]. In practice, because clinical development and regulatory review consume much of that time before approval, effective market exclusivity is often 12–15 years.
That should be enough time to recoup a substantial investment. For most drugs, it is. But for blockbuster biologics generating tens of billions in annual revenue, it is apparently not enough — or at least, originator companies have not behaved as if it were. Instead, they have systematically filed additional patents covering everything tangentially related to the product: specific formulations, delivery devices, manufacturing processes, methods of treatment, patient populations, dosing regimens, and combinations with other drugs [24].
The result is the patent thicket. Humira — adalimumab — was protected by over 250 patents when biosimilars first entered the U.S. market in 2023, 21 years after its original approval [25]. This effectively extended AbbVie’s U.S. exclusivity to nearly four decades. Patent attorney Ha Kung Wong has described the situation directly: “Thickets force biosimilar developers to navigate dozens of overlapping claims, delaying affordable alternatives by years” [25].
The economics behind thicket construction are rational from the originator’s perspective. Humira was generating an estimated $47.5 million per day in revenue before biosimilar entry [25]. Every additional year of exclusivity adds billions to the bottom line. Filing additional patents on formulations, concentrations, or administration methods costs a fraction of that and can delay biosimilar entry through litigation for years.
The consequences for the supply chain are structural. Patent thickets limit the number of manufacturers who can legally produce biosimilars for a given reference product. Fewer manufacturers means less supply diversity, less competition, and a more brittle supply chain that is harder to recover from disruptions. The “weaponization” of patents — a phrase that is technically legal but commercially aggressive — is not just an affordability problem. It is a supply chain resilience problem that affects the entire healthcare system.
The Revlimid (lenalidomide) case provides an extreme example: litigation over that small-molecule drug’s patents lasted 18 years, blocking generic versions even after primary patents had expired [25]. The biosimilar equivalent for complex biologics could be worse, given the sheer number of potential patent claims available to originator companies.
The BPCIA Patent Dance: Strategy, Not Just Process
The Biologics Price Competition and Innovation Act of 2009 established a unique framework for resolving patent disputes between originator companies and biosimilar applicants before commercial launch [26]. This framework — informally called the “patent dance” — is one of the more strategically complex mechanisms in pharmaceutical law, and it has direct implications for supply chain planning.
The dance begins when a biosimilar applicant receives FDA acceptance of their abbreviated Biologics License Application (aBLA). They must then provide the reference product sponsor (RPS, i.e., the originator company) with a confidential copy of the aBLA along with detailed manufacturing information [26]. This is counterintuitive: the biosimilar company, before its product is approved, hands its manufacturing secrets to its competitor.
In return, the RPS has 60 days to provide a list of unexpired patents it believes could be infringed, along with any licensing offers. The biosimilar applicant then has 60 days to respond with invalidity, unenforceability, or non-infringement arguments for each patent. The RPS counters with its own claim-by-claim analysis [26]. This structured exchange — with fixed deadlines and extensive disclosure requirements — is designed to surface all patent issues before commercial launch and facilitate negotiated settlements.
The dance concludes in two litigation phases. Phase I involves agreeing on which patents to litigate immediately (if no agreement, the biosimilar applicant selects and notifies the RPS, who must sue within 30 days). Phase II is triggered by the biosimilar applicant’s notice of intended commercial marketing, given at least 180 days before launch, which allows the RPS to seek preliminary injunctions on remaining patents [26].
The landmark 2017 Supreme Court decision in Sandoz Inc. v. Amgen Inc. fundamentally changed how biosimilar companies approach the dance [27]. The Court confirmed that participation is optional: a biosimilar applicant can bypass the entire information exchange process and instead provide the 180-day commercial marketing notice immediately after FDA acceptance — or even before FDA approval — which triggers litigation directly. This optionality transforms the dance from a mandatory procedure into a strategic choice, one that demands careful legal analysis of the specific patent landscape and the risk/benefit calculation of early disclosure versus faster litigation resolution.
For supply chain leaders, the patent dance matters because it directly affects market entry timing. Engaging in the dance might surface patents that can be challenged pre-approval, potentially clearing the path faster. Bypassing it might accelerate timelines but preserves manufacturing information that a competitor could otherwise use. The decision requires coordination between legal, regulatory, manufacturing, and commercial teams — the kind of cross-functional integration that many pharmaceutical organizations are still building.
Using Patent Intelligence to De-Risk the Supply Chain
The practical reality of navigating patent thickets and the patent dance is that success requires deep, current knowledge of the originator’s patent portfolio before making critical development decisions. This is where specialized intelligence platforms earn their value.
DrugPatentWatch provides biosimilar developers with the granular patent data required to make these decisions analytically rather than on intuition [28]. The platform’s capabilities span several dimensions that directly affect supply chain risk and market entry timing.
Patent landscape mapping — identifying every patent associated with a reference product, its expiration dates, its claim scope, and its litigation history — allows developers to assess which patents represent genuine barriers and which are legally vulnerable [28]. A patent that has been repeatedly challenged at the Patent Trial and Appeal Board (PTAB) in inter partes review (IPR) proceedings, and repeatedly survived, is a different strategic obstacle than one that has never been tested. DrugPatentWatch’s litigation tracking captures this history, enabling more informed prioritization of which patents to challenge and which to design around [28].
Freedom-to-operate analysis — determining whether a specific manufacturing process or formulation avoids infringement of the originator’s patent portfolio — is the other critical function. If a biosimilar developer’s proposed CHO cell line development approach or purification method is covered by an originator’s process patent, they need to know before investing three years in process development, not after [28]. Patent intelligence can identify those risks early enough to influence manufacturing design decisions.
The interaction between patent strategy and supply chain is not obvious but is real. A manufacturing process designed from the outset to avoid infringing specific process patents is a supply chain asset: it reduces the probability of injunctions that halt production, decreases litigation costs, and accelerates the timeline to commercial launch. Companies that treat patent strategy as a legal department concern, separate from manufacturing and supply chain strategy, systematically miss opportunities to make better process design decisions earlier.
Continuous competitive monitoring is the third dimension. DrugPatentWatch allows tracking of competitor patent filings, PTAB proceedings, litigation outcomes, and regulatory submissions across the biosimilar landscape [28]. This intelligence feeds directly into market entry timing decisions, pricing strategy, and supply chain investment planning. Knowing that a competitor has just filed for interchangeability designation for an adalimumab biosimilar, or that a key Remicade formulation patent has been invalidated at PTAB, changes commercial planning in real time.
Part Four: Regulatory Pathways — Global Divergence as a Market Access Problem
FDA vs. EMA: Where the Frameworks Agree and Where They Split
Both the FDA and EMA operate on the same foundational principle for biosimilar approval: demonstrate that the biosimilar is highly similar to the reference product, with no clinically meaningful differences in safety, purity, and potency [5][6]. The evidence hierarchy both agencies use — analytical characterization first, then non-clinical studies if needed, then clinical studies — is also shared, with increasing regulatory reliance on analytical data as the primary basis for approval as the science matures.
The differences, however, are operationally significant. The EMA, which launched its biosimilar approval pathway in 2005 — four years before the U.S. BPCIA — has historically required more extensive clinical testing for certain products, particularly efficacy trials in sensitive clinical models [29]. The FDA’s approach has evolved toward accepting robust analytical and pharmacokinetic/pharmacodynamic data as primary evidence, reducing or eliminating clinical efficacy trials for many products where the mechanism of action is well-understood [29].
Several other divergences complicate global development programs. Some jurisdictions still require locally sourced reference products for comparability studies — a requirement that adds cost and timeline to multi-regional programs. Certain countries outside the U.S. and EU still mandate comparative animal toxicology studies that most major health authorities have abandoned as uninformative [29]. Clinical study design requirements differ; specific patient population data for local ethnic groups is required in some Asian markets. Post-market pharmacovigilance requirements — including mandatory adverse event reporting systems, periodic safety update reports, and risk management programs — vary significantly across regions [30].
For a biosimilar developer targeting multiple markets simultaneously, these differences force difficult choices. Running parallel development programs that satisfy all regulatory requirements is expensive and often results in redundant studies. Prioritizing specific markets means accepting delayed entry into others. Regulatory harmonization efforts — including collaboration between the International Council for Harmonisation (ICH) and various health authorities — have made progress but have not eliminated these divergences.
The practical supply chain implication is that regulatory divergence slows the proliferation of approved biosimilar manufacturers across markets. Fewer approved manufacturers in a given region means less supply resilience in that region. A supply disruption affecting a manufacturer whose product is approved only in the EU, for instance, cannot easily be covered by a manufacturer whose product is approved only in the U.S. Regional regulatory approval strategies directly constrain global supply chain flexibility.
Interchangeability: The Formulary Lever
The FDA’s interchangeable biosimilar designation represents one of the most commercially significant regulatory decisions a biosimilar company can pursue in the U.S. market. An interchangeable biosimilar can be substituted for its reference product at the pharmacy level without physician involvement — essentially the same mechanism used for generic small-molecule drugs [31].
To receive interchangeability designation, a biosimilar must demonstrate not only the standard biosimilarity package but also that it produces the same clinical result as the reference product in any given patient, and that alternating or switching between the biosimilar and reference product does not produce additional safety risks or reduce efficacy [31]. Historically, this required a dedicated switching study — a clinical trial in which patients alternated between the biosimilar and reference product multiple times to detect any adverse effects of switching.
FDA draft guidance issued in 2024 signaled potential flexibility in this requirement, suggesting that existing analytical and pharmacokinetic/pharmacodynamic data, combined with clinical data already submitted for biosimilarity, might be sufficient to support an interchangeability designation for some products [32]. If finalized, this would reduce the cost and timeline associated with interchangeability — making it a more attractive strategic investment for a larger number of biosimilar developers.
The commercial importance of interchangeability has been demonstrated clearly. Humira biosimilars that received interchangeability designation — including adalimumab-aaty (Yuflyma) in 2023 and adalimumab-ryvk (SIMLANDI) — gained access to pharmacy-level automatic substitution in states that allow it [33]. This shifts the competitive dynamic from physician-level prescribing decisions — where education, trust, and clinical inertia favor the reference product — to pharmacy-level decisions, where formulary algorithms and payer incentives favor the lower-cost product.
Without interchangeability, biosimilar adoption depends heavily on physician willingness to actively prescribe the biosimilar over the reference product. In the U.S. market, where physician prescribing habits are shaped by years of originator marketing, clinical familiarity, and sometimes explicit or implicit financial incentives, this has proven to be a slow process. Interchangeability bypasses that friction, at least partially.
For supply chain planning, interchangeability has a direct implication: it can produce faster volume ramp-up than non-interchangeable biosimilars. A biosimilar that achieves interchangeability in a major PBM’s formulary can see volume shift rapidly once formulary positions are locked in — the CVS Caremark decision on Humira biosimilars in 2024 is the best-documented example. That speed of volume ramp requires supply chain readiness that cannot be improvised at launch.
Part Five: Market Dynamics — Forecasting the Unforecastable
Why Standard Demand Models Fail Biosimilars
Pharmaceutical demand forecasting typically relies on historical prescribing data, disease prevalence trends, treatment guideline changes, and competitive entry models. Biosimilars break most of these inputs.
For any given reference biologic, the biosimilar market is new by definition: there is no historical biosimilar data to extrapolate from. Treatment patterns in patients already on the reference product are established, but how quickly those patients transition to biosimilars — whether through payer mandates, physician prescribing, or automatic pharmacy substitution — depends on payer policy decisions, interchangeability status, and physician education campaigns, none of which can be forecast with precision from historical data [34].
The demand forecasting problem is compounded by market structure. When a reference product’s patents expire, multiple biosimilar applicants typically enter or attempt to enter simultaneously. Their relative market share depends on pricing strategies, interchangeability status, formulary placement decisions, and originator counter-strategies — all of which interact dynamically and non-linearly [34]. A single PBM formulary decision can shift tens of millions of prescriptions within a quarter. These are discontinuous jumps that smooth extrapolation models cannot capture.
IQVIA’s research on biosimilar forecasting has documented the scale of this problem [34]. Companies regularly overestimate biosimilar uptake in the first 12–24 months after launch, leading to overinvestment in manufacturing capacity and sales infrastructure that then has to be written down. The Humira experience was illustrative: multiple biosimilars launched in 2023 with aggressive pricing and significant commercial infrastructure, yet the branded product retained an astonishing 96% market share more than a year later, primarily because of AbbVie’s rebate agreements with PBMs [35]. The formulary shift that eventually drove biosimilar adoption — CVS Caremark’s decision to remove brand Humira from its formularies in April 2024 — was not predictable from a standard market model.
The operational consequence is that biosimilar supply chains need to be designed for optionality, not optimization. Manufacturing capacity that can be scaled up or down relatively quickly — through flexible contracts with CDMOs, modular facility designs, or adjustable batch sizes — is more valuable in this environment than capacity optimized for a single volume projection that will almost certainly be wrong.
The Payer-Manufacturer Dynamic: Where Supply Chain and Commercial Strategy Intersect
The single largest driver of biosimilar market penetration in the U.S. is not product quality, regulatory approval, or even price. It is formulary placement.
Pharmacy Benefit Managers (PBMs) — primarily CVS Caremark, Express Scripts, and OptumRx, which collectively manage prescription benefits for roughly 270 million Americans — determine which drugs are on their formularies at what cost-sharing tiers [36]. Their decisions are largely driven by rebate negotiations with manufacturers. Originator companies have used this leverage aggressively: Humira’s market persistence despite the availability of biosimilars at 80–85% discounts is explained almost entirely by AbbVie’s ability to offer PBMs rebates large enough to offset the biosimilar price advantage [35].
This creates a structural problem for the biosimilar supply chain. Biosimilar manufacturers invest in manufacturing infrastructure, regulatory programs, and commercial launch capabilities based on volume projections. Those projections assume that price will be the primary driver of adoption. When rebate agreements block price from being the primary driver, the volume projections are wrong, the manufacturing investment is stranded, and some manufacturers exit the market. This reduces supply diversity, making the supply chain more fragile for everyone — including the patients the system was designed to serve.
The Inflation Reduction Act (IRA) took a direct step toward addressing this by increasing Medicare reimbursement for biosimilars to ASP plus 8% of the reference biologic’s ASP [37]. This creates an economic incentive for physicians and providers to prescribe biosimilars in the Medicare setting — one of the few policy levers that directly counteracts the rebate-driven formulary distortion. Earlier, CMS modifications to the Medicare payment model for infliximab biosimilars, starting in 2019, had similar effects [38].
For biosimilar manufacturers, the lesson from Humira and Remicade is that commercial strategy and supply chain strategy cannot be developed independently. The commercial decision about how to negotiate with PBMs — whether to compete on list price, offer your own rebates, pursue a private-label arrangement, or target specific geographic markets where formulary dynamics differ — directly determines the volume profile your supply chain will need to support. Supply chain planning built on commercial assumptions that prove wrong is not just inefficient; it is strategically dangerous.
Multiple Entrants and the Price Erosion Problem
When multiple biosimilars enter a market segment simultaneously, as happened with adalimumab after 2023, price competition intensifies rapidly [39]. The discounts biosimilar manufacturers offer to payers can reach 40–86% off the reference product’s wholesale acquisition cost (WAC), depending on competitive dynamics and urgency for formulary placement [35].
This price erosion creates the paradox noted earlier. Aggressive price competition benefits payers and patients in the short term but erodes manufacturer economics to the point where sustaining investment in that biosimilar is questionable. Companies that entered the adalimumab market with biosimilars priced at 85% discounts are operating on thin margins, particularly if their commercial volume is lower than projected due to rebate barriers.
The resulting market structure tends toward consolidation. Manufacturers with high-volume, low-cost production capabilities — typically those with large-scale manufacturing facilities in cost-competitive geographies — survive. Smaller or higher-cost producers exit. This is economically rational for individual companies but produces a supply chain risk for the healthcare system: concentration among fewer manufacturers increases vulnerability to production disruptions at any single site.
Interchangeability is one strategic response. A biosimilar with interchangeable status can command formulary placement that generates higher volume, potentially sustaining economics at lower margins. Portfolio-level contracting — where a biosimilar manufacturer bundles multiple products across different therapeutic areas to offer PBMs broader value — is another. Both require commercial sophistication that is fundamentally a supply chain enabler: they protect the volume base that justifies continued manufacturing investment.
Part Six: Building Resilience — The Operational Playbook
Diversification: Geography, Suppliers, and Technology
Supply chain diversification for biosimilars operates on multiple dimensions simultaneously, and companies that treat it as a single strategy — “we’ll add a second supplier” — miss most of the value.
Geographic diversification is the most visible dimension. Over-reliance on a single region for raw material sourcing or manufacturing creates exposure to geopolitical disruption, export restrictions, quality-control variability, and logistics delays [40]. McKinsey has estimated that up to 60% of pharmaceutical sourcing could theoretically be diversified across geographic locations without significant quality compromise [41]. The practical path runs through Southeast Asia, Eastern Europe, and Mexico as manufacturing alternatives to China and India, with some companies pursuing reshoring to the U.S. or Europe for strategically critical components.
Supplier diversification within each geography is the second dimension. Maintaining approved alternatives for critical raw materials — not just approved in theory, but qualified and periodically validated through actual production runs — is the difference between a diversification program that exists on paper and one that actually works. The 24-month qualification timeline for new suppliers means that alternative supply relationships need to be established when production is running smoothly, not when a disruption has already occurred.
Manufacturing technology diversification is increasingly relevant for biosimilars. The shift from traditional batch bioprocessing to continuous manufacturing — where the bioreactor runs continuously rather than in discrete batches — changes the risk profile significantly. Continuous processes can reduce variability, decrease the production footprint required, and enable real-time quality monitoring through Process Analytical Technology (PAT) [42]. Single-use bioreactor systems, rather than traditional stainless steel tanks, reduce cleaning requirements and contamination risk while enabling faster changeovers between products. Companies that have invested in these technologies have more manufacturing flexibility than those locked into traditional batch infrastructure.
Inventory strategy is the fourth dimension. The biosimilar industry’s shift away from just-in-time inventory management toward “just-in-case” buffers reflects the higher risk profile of biologic supply chains [43]. What counts as an adequate buffer varies by product: a biosimilar with a short shelf life (say, 18 months) cannot buffer as aggressively as one with a 36-month shelf life without risking waste. But the principle — maintaining finished goods, API, and raw material buffers beyond what pure demand optimization would suggest — is sound. The cost of buffer inventory is quantifiable; the cost of a stockout in a healthcare context is not.
CDMOs as Strategic Infrastructure
The CDMO industry has grown substantially in parallel with the biosimilar market, and for good reason. Building a commercial-scale biologic manufacturing facility requires capital investment of $300–600 million or more, plus the specialized workforce and regulatory infrastructure to operate it [44]. For biosimilar developers whose core competency is science and commercial execution rather than manufacturing operations, that capital is better deployed elsewhere.
CDMOs bring several things that most biosimilar developers cannot easily build internally. Manufacturing expertise and infrastructure at commercial scale is the most obvious. But the less obvious assets may be more valuable: regulatory relationships and submission expertise across multiple markets, technology transfer capabilities for moving processes from development-scale to production-scale, and continuous process improvement programs that optimize yield and quality over the product lifecycle [44].
The end-to-end CDMOs — those that can take a biosimilar project from initial cell line development through commercial manufacturing, handling regulatory submissions along the way — are particularly valuable for companies entering their first biologic or biosimilar. They compress the timeline from IND filing to commercial launch and reduce the regulatory risk that comes from inexperience with FDA or EMA biologic submission requirements [44].
The risk in CDMO relationships is dependency. A biosimilar manufacturer that relies on a single CDMO for all production has not diversified its manufacturing risk; it has transferred it. Best practice requires either multiple CDMO partnerships for the same product (with appropriate technology transfer and regulatory approval at each site) or a CDMO relationship combined with meaningful internal manufacturing capability. The industry trend toward collaborative risk-sharing models in CDMO contracts — where both parties share in upside and downside outcomes rather than operating purely on fixed-fee arrangements — reflects a maturing understanding that aligned incentives produce better manufacturing outcomes [44].
AI-Driven Demand Intelligence
Artificial intelligence and machine learning are not solving the fundamental unpredictability of biosimilar markets, but they are making it more manageable. The core application is demand forecasting: analyzing historical sales data, prescription trends, payer formulary changes, competitor activity, and external signals (including social media sentiment and epidemiological data) to produce forecasts with quantified uncertainty ranges [45].
Traditional biosimilar demand models struggle because they extrapolate from limited historical data and assume relatively smooth adoption curves. AI-based models can incorporate the discontinuous effects of formulary decisions and policy changes more effectively, by training on patterns from previous biosimilar launches across different therapeutic areas and markets. They can also update in real time as new data arrives — detecting early signals of adoption acceleration or deceleration that would not be visible in quarterly reporting [45].
In manufacturing quality control, AI applications are advancing rapidly. Computer vision systems can detect subtle defects in vials and packaging at speeds and accuracy levels that human inspectors cannot match. Machine learning algorithms trained on historical batch data can predict the probability of a batch failing quality release before the batch is complete — enabling earlier intervention and reducing waste [46]. Process monitoring systems that continuously analyze bioreactor performance data can detect subtle drifts in culture conditions before they affect product quality, triggering adjustments in real time.
One of the most significant applications is in cell line development. Selecting the highest-producing, most stable cell line from a panel of candidates is traditionally a time-consuming empirical process. AI algorithms trained on the genomic and proteomic characteristics of cell lines can predict productivity and stability, dramatically reducing the number of candidates that need to be evaluated experimentally [46]. This compresses development timelines and improves the probability of selecting a cell line that will perform consistently at commercial scale.
Merck’s deployment of IoT sensors combined with predictive analytics in its manufacturing facilities provides a real-world benchmark: the company reported a 20% improvement in production uptime as a result [47]. Pfizer’s cold chain control tower — a 24/7 monitoring system for temperature-sensitive product shipments — allows intervention when real-time tracking shows a route deviation or temperature excursion, before product is lost [47].
The companies achieving measurable results from AI in supply chain operations share several characteristics: they have invested in data infrastructure (clean, well-labeled historical data is the prerequisite for effective machine learning), they have integrated AI tools into operational decision-making processes rather than treating them as analytical curiosities, and they have leadership with enough technical literacy to evaluate AI output critically rather than treating it as a black box.
Blockchain for Cold Chain Integrity and Counterfeit Prevention
Blockchain’s appeal to pharmaceutical supply chains stems from a property that happens to solve one of the sector’s most persistent problems: creating a tamper-proof, shared record of events across multiple participants who do not fully trust each other.
A biosimilar passes through many hands between manufacturing and patient: bulk drug substance shipped from a bioreactor facility, filled and finished at a separate site, packed and labeled, warehoused, distributed to wholesalers, then to pharmacies or hospital systems, and finally dispensed to patients. At each handoff, temperature conditions, custody, and identity should be recorded. But those records currently exist in different systems maintained by different organizations, with no shared verification mechanism.
Blockchain creates a distributed ledger — a single shared record of all transactions — that is cryptographically secured against retroactive modification [48]. Any participant with permission can view the record; no single participant can alter it unilaterally. Applied to a pharmaceutical supply chain, this means that a temperature excursion recorded at a distribution center in Phoenix cannot be quietly deleted from the records — it is permanently on the ledger, visible to all parties.
The Drug Supply Chain Security Act (DSCSA) in the U.S. — which requires pharmaceutical manufacturers, wholesalers, and dispensers to track and trace products at the unit level — is driving adoption of these capabilities [48]. The MediLedger Consortium, which includes Pfizer, Gilead Sciences, and other major pharmaceutical companies, has built a working Ethereum-based blockchain system for verifying drug authenticity and tracking transaction histories across DSCSA requirements [49]. The system has reduced counterfeit drug incidents and streamlined product recall processes by providing complete, auditable transaction histories.
Counterfeit biologics are a genuine public health risk. In markets with less regulatory oversight, counterfeit products have been documented for high-value biologics including monoclonal antibodies used in cancer treatment [48]. Blockchain-based authentication — where QR codes or serialized identifiers can be scanned to verify product origin against an immutable ledger — provides a verification mechanism that is far more robust than paper-based systems.
For biosimilar manufacturers, blockchain implementation does not require building proprietary systems. Participating in industry consortia like MediLedger or partnering with established platforms reduces the technical burden and achieves the interoperability that makes the system valuable [49]. The investment in blockchain integration pays returns primarily in regulatory compliance efficiency, counterfeit risk reduction, and the operational speed of product recalls — which, when a recall is necessary, matters enormously.
Digital Twins and Process Simulation
One technology deserves specific mention beyond AI and blockchain: digital twin manufacturing simulation.
A digital twin is a continuously updated computational model of a physical system — in this context, a bioreactor, a purification train, or an entire manufacturing facility — that can be used to simulate process changes virtually before implementing them physically [47]. Novartis has deployed digital twin technology to simulate production processes across its global manufacturing network, using it to test process changes, validate tech transfers between sites, and optimize batch parameters without consuming physical manufacturing capacity [47].
For biosimilars, digital twins are particularly valuable at two moments. The first is process development, where the number of experimental conditions that need to be tested physically can be dramatically reduced by running simulations first. The second is technology transfer — moving a manufacturing process from a development facility to a commercial manufacturing site, or from one commercial site to another. Technology transfer failures are one of the most common causes of supply disruption for biologics; digital twin simulations that predict how a process will behave in a different physical environment can identify problems before they become regulatory findings [47].
Part Seven: Sustainability and Ethics in Biosimilar Supply Chains
Environmental Footprint: From Liability to Competitive Signal
Biomanufacturing is energy-intensive. Cleanrooms require HVAC systems running continuously at high air change rates. Bioreactors consume electricity for mixing, aeration, and temperature control. Purification processes use large volumes of ultra-pure water. Single-use systems — bioreactor bags, tubing, filters — reduce the energy and chemical consumption associated with cleaning stainless steel equipment but generate substantial plastic waste [50].
The pharmaceutical industry’s environmental footprint has attracted increasing scrutiny from investors, regulators, and potential employees who factor sustainability performance into their decisions. Companies with strong environmental performance attract lower-cost capital from ESG-focused funds and face fewer regulatory headwinds as carbon pricing and environmental disclosure requirements expand.
The operational connection to supply chain is direct. Reducing energy consumption per batch lowers manufacturing cost and carbon intensity simultaneously. Facility siting decisions that place manufacturing closer to renewable energy grids or raw material sources reduce transportation emissions and logistics costs [50]. Process optimization that reduces water consumption decreases operating costs in water-stressed regions. Environmental sustainability and operational efficiency are not in tension for biomanufacturing — they overlap substantially.
Single-use system waste is the area of greatest tension. The plastic waste generated by single-use bioreactor bags, tubing, and disposable chromatography columns is difficult to recycle because pharmaceutical waste streams require specialized handling [50]. Industry consortia and equipment manufacturers are developing recycling programs for pharmaceutical single-use plastics, but adoption is still limited. Companies that get ahead of this problem — through equipment redesign, supplier partnerships for take-back programs, or investment in recycling infrastructure — will face fewer regulatory pressures as this issue scales.
Ethical Sourcing: The Human Dimension of Raw Material Supply
The same globalized supply chains that create raw material procurement vulnerabilities also create ethical exposure. Pharmaceutical raw material production in some geographies involves labor conditions — working hours, safety standards, environmental protections — that do not meet the standards companies apply to their own facilities [51].
The Pharmaceutical Supply Chain Initiative (PSCI) has established Principles for Responsible Supply Chain Management covering ethics, labor, health and safety, environment, and management systems [52]. Leading pharmaceutical companies, including Pfizer, have aligned their supplier conduct expectations with these principles and implemented audit programs to verify compliance [53].
For biosimilar manufacturers, ethical sourcing is both a risk management issue and a market positioning opportunity. Procurement decisions that ignore labor and environmental conditions in the supply chain create exposure to reputational damage, regulatory investigation, and supply disruption when ethicized trading partners exit problematic relationships. Procurement decisions that actively screen for ethical compliance create resilience against these risks and increasingly differentiate companies in markets where institutional buyers — hospitals, health systems, government programs — are applying social procurement criteria.
Patient-centricity extends into supply chain ethics in a less obvious way. Biosimilars create cost savings that should translate into reduced patient out-of-pocket costs and expanded access to therapies. When supply chain failures — either physical disruptions or commercial dynamics like rebate-driven formulary exclusion — prevent that translation, the ethical case for biosimilar investment is weakened. Supply chain resilience is, in this sense, a patient care issue, not just an operational one.
Part Eight: Case Studies — What the Humira and Remicade Launches Actually Teach Us
Adalimumab (Humira): A Market That Required a Payer Decision to Move
The Humira biosimilar market entry in the U.S. is the most exhaustively documented biosimilar launch in history, and its lessons are largely counterintuitive.
The setup appeared favorable. Multiple biosimilar manufacturers had FDA approval by 2023. Products were priced at 80–85% discounts to Humira’s WAC. Interchangeability designations were in progress. The patent thicket — over 250 patents — had been navigated through a combination of licensing agreements (AbbVie settled with most biosimilar manufacturers, granting U.S. launch rights starting January 2023) and litigation outcomes [35].
Yet brand Humira retained approximately 96% market share more than a year after the first biosimilar launched [35]. The explanation is simple: AbbVie’s rebate agreements with major PBMs, which had been structured years in advance of biosimilar entry, made brand Humira economically preferable to PBMs despite its higher list price. The biosimilars were available; the commercial infrastructure blocked them.
The market shifted decisively only in April 2024, when CVS Caremark removed brand Humira from its formularies in favor of biosimilar adalimumab — specifically its own-label product [35]. This single payer decision produced a faster market share shift than 14 months of biosimilar availability at dramatic discounts. Brand Humira’s market share dropped to 81% by May 2024 and continued declining.
The operational implications for biosimilar companies are significant. First, supply chain capacity planning cannot be based on simple assumptions about price-driven adoption. Formulary decisions are binary and unpredictable; they require supply chains capable of rapid volume ramp without degrading product quality or reliability. Second, interchangeability matters specifically because it enables the pharmacy-level substitution that PBM formulary decisions trigger: without interchangeability, even a favorable formulary position requires physician cooperation at the prescription level. Third, companies that build private-label or PBM-partnership models — where the PBM has a direct stake in biosimilar success — can align commercial incentives in ways that generic formulary positioning cannot [35].
The cold chain and manufacturing execution for Humira biosimilars has not, by most accounts, been the primary challenge. The biosimilars that launched in 2023 have generally met their manufacturing and distribution quality requirements. The supply chain challenge was commercial, not operational — but it was still a supply chain challenge, because uncommitted manufacturing capacity costs money whether product moves or not.
Infliximab (Remicade): When Patent Strategy and Commercial Contracts Both Block Competition
The infliximab biosimilar experience, starting in 2016 with Inflectra (infliximab-dyyb) and Renflexis (infliximab-abda), documents a more multi-dimensional defense strategy by Janssen (Johnson & Johnson).
Janssen’s IP strategy began with patent thicketing — filing numerous patents on formulations and methods of treatment that extended Remicade’s patent protection to what is estimated at 27 years from original approval [38]. The patent dance was engaged and litigated extensively, generating substantial legal costs for biosimilar manufacturers and delaying commercial launch [38]. Janssen was simultaneously accused of exclusionary contracting — bundling Remicade with other Janssen products in hospital purchasing agreements in ways that effectively penalized institutions for using biosimilar alternatives [38]. These contracts were the subject of antitrust litigation, reflecting the emerging legal theory that biosimilar market access has antitrust dimensions beyond pure patent law.
The result was slow adoption. Infliximab biosimilars captured only about 10% of the infliximab market two years after launch and only 44% by 2023 — significantly slower penetration than was achieved in European markets, where rebate structures are less dominant and biosimilar substitution policies are more aggressive [38].
The manufacturing reality for infliximab is instructive about raw material complexity. Remicade’s supply chain involves procurement of hundreds of raw materials from over 60 suppliers, with qualification processes taking up to 24 months per new supplier and procurement lead times of 16–24 weeks [16]. This complexity means that biosimilar manufacturers’ ability to respond to supply disruptions or scale production rapidly is constrained not just by bioreactor capacity but by raw material availability windows.
Janssen’s eventual response — launching an unbranded infliximab product at a lower list price than Remicade but higher than the biosimilars — illustrated the defensive flexibility that originator companies retain even after biosimilar entry [38]. This “authorized generic” strategy acknowledges biosimilar competition while attempting to retain market share within the originator’s own portfolio. It complicates biosimilar manufacturers’ volume projections by introducing a third product category with different pricing and formulary dynamics than either the branded reference or the biosimilar.
The policy interventions that eventually shifted the infliximab market toward biosimilars — CMS reimbursement changes, the Purple Book Continuity Act requiring public patent listing — underscore a broader lesson from both the Humira and Remicade cases: market forces alone are often insufficient to drive biosimilar adoption against a well-resourced originator defense. Regulatory and policy infrastructure matters as much as manufacturing and commercial capability.
Part Nine: Real-World Evidence — The Regulatory Feedback Loop
How RWE Is Changing Post-Market Surveillance
Post-market surveillance for biosimilars has traditionally focused on safety pharmacovigilance — detecting adverse events not identified in pre-approval clinical studies, tracking immunogenicity in broader patient populations, and identifying any signals of reduced efficacy in real-world use [30]. This remains central, but the scope of real-world evidence (RWE) in biosimilar regulation is expanding.
The FDA is explicitly committed to using real-world data (RWD) — from electronic health records, claims data, registries, and patient-generated health data — to generate evidence that supports regulatory decisions throughout the product lifecycle, not just post-approval safety monitoring [54]. This includes potential use of RWE to support expanded indications, to inform the comparability exercises for new biosimilar applicants seeking to use established biosimilars as reference products, and to monitor the performance of biosimilars in patient subgroups underrepresented in clinical trials.
For the supply chain, the expanding role of RWE creates both obligations and opportunities. The obligation is building data collection and pharmacovigilance infrastructure capable of generating fit-for-purpose RWD at commercial scale. The opportunity is that robust RWE demonstrating real-world biosimilar safety and effectiveness — particularly in areas where physician hesitancy has been driven by immunogenicity concerns — can accelerate market adoption by providing evidence beyond what clinical trials can generate.
Global harmonization of RWE standards — how data is collected, what statistical methods are acceptable, what constitutes a fit-for-purpose dataset for regulatory submissions — is still in progress. The ICH and bilateral regulatory collaboration programs between FDA, EMA, and other major health authorities are working toward alignment, but the timelines are long and the stakes are high enough that companies should monitor developments closely. A biosimilar developer that builds its RWE program to FDA standards may find those standards insufficient for EMA submission or vice versa.
Key Takeaways
Biosimilars are a growth market with structural fragility. The market is expanding toward $175–357 billion by 2034, driven by patent expirations and cost pressure. But that growth depends on supply chains that are inherently complex, legally constrained, and commercially unpredictable. Companies that treat biosimilar supply chains as scaled-up small-molecule supply chains will underinvest in the right places.
Manufacturing complexity starts before the bioreactor. Raw material sourcing — cell culture media, critical reagents, supplier qualification — is where many biosimilar supply chain problems originate. The 24-month qualification timeline for new suppliers means that diversification must be built during stable production, not after disruptions occur.
Cold chain is a competitive moat, not a compliance box. Companies with superior cold chain infrastructure can serve broader geographic markets, absorb disruptions without product loss, and demonstrate supply chain reliability to payers and health systems. Inferior cold chain capability limits market reach and creates patient safety risk.
Patent thickets are supply chain problems, not just legal problems. Originator patent strategies that delay biosimilar entry also limit supply diversity, making the healthcare system more vulnerable to manufacturing disruptions. Patent intelligence platforms like DrugPatentWatch enable developers to identify vulnerable patents, design manufacturing processes that avoid infringement, and make informed decisions about engaging or bypassing the BPCIA patent dance — all of which directly affect time-to-market and supply chain readiness.
Market penetration is driven by commercial and policy decisions as much as supply chain execution. The Humira case demonstrated that biosimilar volume can be blocked for over a year by PBM rebate agreements despite product availability. Supply chain planning must account for commercial scenario uncertainty with flexible manufacturing capacity rather than single-point volume projections.
Digital transformation reduces but does not eliminate supply chain risk. AI, blockchain, and IoT technologies provide genuine improvements in demand forecasting accuracy, quality control, traceability, and cold chain integrity. They work best when integrated into operational decision-making processes and supported by clean, well-structured data infrastructure.
Sustainability and ethics are becoming supply chain requirements. ESG-conscious investors, institutional buyers applying social procurement criteria, and expanding regulatory disclosure requirements are converting environmental and ethical supply chain performance from optional differentiation into baseline expectation.
FAQ
Q1: Why do biosimilar manufacturers face fundamentally different supply chain economics than generic drug manufacturers, and what does that mean for pricing strategy?
Generic drug manufacturers operate with relatively thin margins on individual products because their manufacturing costs are low (chemical synthesis), their capital requirements are modest, and competition is intense. They compensate with volume across broad product portfolios. Biosimilar manufacturers face fundamentally different economics: biologic manufacturing requires $300–600 million in capital investment for a commercial-scale facility, raw material procurement and qualification costs are high, cold chain distribution adds 15–25% to logistics costs compared to ambient distribution, and quality control requires sophisticated analytical capabilities that small-molecule manufacturers do not need [44]. These structural cost differences mean that biosimilar pricing cannot erode as far as small-molecule generic pricing without destroying the economics of continued supply. Companies that price biosimilars based on competitive pressure rather than cost-plus analysis risk creating supply commitments they cannot sustainably fulfill — which ultimately harms patients and the healthcare system they were meant to benefit.
Q2: How should a biosimilar developer think about the decision to pursue interchangeability designation, given the additional cost and development time?
The interchangeability calculation depends on the specific market and product. In the U.S., interchangeability enables pharmacy-level automatic substitution in states that allow it — a capability that is particularly valuable in markets dominated by PBM formulary management, where a formulary position that includes interchangeable substitution generates faster volume ramp-up than one that requires physician prescribing action. The question to ask is: given the likely payer and formulary dynamics for this product, what volume difference would interchangeability produce over the first 24 months, and does the net present value of that volume difference exceed the cost of the additional development program? For high-volume reference products like adalimumab or infliximab, the answer is often yes. For lower-volume specialty biologics, the calculus may be different. FDA’s draft 2024 guidance potentially reducing the switching study requirement for interchangeability may change this calculation for products where the incremental clinical program was the primary cost driver [32].
Q3: What specific supply chain risks are created by the concentration of active pharmaceutical ingredient (API) manufacturing for biologics in a small number of geographies?
Biologic API manufacturing — the upstream fermentation and purification that produces the drug substance before formulation and filling — is concentrated in a relatively small number of large-scale facilities, primarily in the U.S., Western Europe, and East Asia [40]. This concentration creates three categories of supply risk. First, geopolitical risk: trade disputes, export restrictions, or sanctions affecting key geographies can block access to manufacturing capacity or raw materials with very little warning. Second, natural disaster and pandemic risk: a major production facility in a hurricane-prone coastal region or a region affected by a pandemic is a single point of failure for all products manufactured there. Third, regulatory risk: a serious finding by FDA or EMA at a major manufacturing facility — contamination, data integrity problems, GMP violations — can result in a Warning Letter or import alert that takes that facility’s output off the market for months while remediation occurs. Biosimilar developers managing this risk need either dual-sourcing for critical API production (with both sites fully approved for each product) or significant finished-goods inventory buffers that can bridge a manufacturing site shutdown of 6–12 months.
Q4: How does the patent dance optionality introduced by Sandoz v. Amgen affect supply chain launch planning?
Before the Sandoz v. Amgen decision, biosimilar applicants had to engage in the patent dance before providing the 180-day commercial marketing notice that starts the clock on Phase II litigation. The Supreme Court’s confirmation that the dance is optional — and that the 180-day notice can be provided even before FDA approval — gave biosimilar developers a significant timing tool [27]. By bypassing the dance, a developer avoids the mandatory disclosure of manufacturing information to the originator but also forgoes the structured pre-approval patent resolution process that the dance provides. From a supply chain perspective, the key variable is how much manufacturing investment should precede resolution of patent uncertainty. A developer who bypasses the dance and provides early commercial marketing notice may find itself launching into litigation-driven injunction risk — potentially having to halt commercial production that has already been scaled up. The risk-appropriate approach is to integrate patent litigation scenario planning directly into supply chain investment timelines, with contingency plans for each outcome rather than single-path commercial launch planning.
Q5: What does the adoption of real-world evidence in biosimilar regulation mean for post-launch pharmacovigilance obligations, and how should supply chain teams plan for them?
The FDA’s commitment to using RWD for regulatory decision-making throughout the product lifecycle means that biosimilar manufacturers’ obligations do not end at commercial launch [54]. Robust pharmacovigilance infrastructure — capable of collecting adverse event data, immunogenicity signals, and effectiveness data from real-world use at the scale of the commercial population — is now expected and will increasingly be a condition of maintaining marketing authorization. For supply chain teams, this has a specific implication: product serialization, traceability, and lot-level tracking that supports pharmacovigilance signal attribution are supply chain functions. When a safety signal emerges in real-world data, the ability to identify which patients received which lots of product, from which manufacturing batches, under what storage conditions, depends entirely on supply chain traceability systems. Companies that build these systems to meet DSCSA compliance requirements — but no further — will find them inadequate for the pharmacovigilance RWE programs that regulators are beginning to expect [48][54].
References
[1] IQVIA Institute for Human Data Science. (2023). Assessing the biosimilar void in the U.S. IQVIA. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/assessing-the-biosimilar-void-in-the-us
[2] Chemaxon. (n.d.). Small molecules vs. biologics. https://chemaxon.com/blog/small-molecules-vs-biologics
[3] Allucent. (n.d.). Points to consider in drug development for biologics and small molecules. https://www.allucent.com/resources/blog/points-consider-drug-development-biologics-and-small-molecules
[4] PMC/NCBI. (2025). Innovative formulation strategies for biosimilars: Trends focused on buffer-free systems, safety, regulatory alignment, and intellectual property challenges. https://pmc.ncbi.nlm.nih.gov/articles/PMC12196224/
[5] European Medicines Agency. (n.d.). Biosimilar medicines overview. https://www.ema.europa.eu/en/human-regulatory-overview/biosimilar-medicines-overview
[6] Synapse Patsnap. (n.d.). What is a biosimilar? FDA vs. EMA approval requirements compared. https://synapse.patsnap.com/article/what-is-a-biosimilar-fda-vs-ema-approval-requirements-compared
[7] Biospace. (2025, February 26). Biosimilars market size estimated to reach USD 175.99 billion by 2034. https://www.biospace.com/press-releases/biosimilars-market-size-estimated-to-reach-usd-175-99-billion-by-2034
[9] DataMintelligence. (n.d.). Biosimilars (US and EU) strategic pharmaceutical CI insights. https://www.datamintelligence.com/strategic-insights/biosimilars-us-and-eu
[10] GlobeNewswire. (2025, July 24). Biosimilars markets global forecast report 2025–2035. https://www.globenewswire.com/news-release/2025/07/24/3120835/0/en/Biosimilars-Markets-Global-Forecast-Report-2025-2035.html
[11] Number Analytics. (2025, June 17). Economics of biosimilars: Cost savings and market dynamics. https://www.numberanalytics.com/blog/economics-biosimilars-cost-savings-market-dynamics
[12] IQVIA Institute for Human Data Science. (2023). Biosimilar savings projections. IQVIA.
[14] PMC/NCBI. (n.d.). A biosimilar drug is defined in the US FDA guidance document as a biopharmaceutical that is highly similar to an already licensed biologic product. https://pmc.ncbi.nlm.nih.gov/articles/PMC5698755/
[15] Bioprocess Online. (n.d.). Cell culture media sourcing center. https://www.bioprocessonline.com/solution/cell-culture-media-sourcing-center
[16] PMC/NCBI. (n.d.). Procurement of raw materials and disposables. https://pmc.ncbi.nlm.nih.gov/articles/PMC6182491/
[17] Cytiva Life Sciences. (n.d.). Cell culture material variability. https://www.cytivalifesciences.com/en/us/knowledge-center/Cell-culture-material-variability
[18] Drug Discovery Online. (n.d.). Understanding and controlling raw material variation in cell culture media. https://www.drugdiscoveryonline.com/doc/understanding-and-controlling-raw-material-variation-in-cell-culture-media-0001
[19] SpendEdge. (n.d.). The biggest problems with pharmaceutical raw materials market, and how you can fix it. https://www.spendedge.com/blogs/problems-pharmaceutical-raw-materials/
[20] ArXiv. (n.d.). Effects of geopolitical strain on global pharmaceutical supply chain design and drug shortages. https://arxiv.org/html/2308.07434v3
[21] PMC/NCBI. (n.d.). Delivering biologics, while maintaining the cold chain, whether standard (2°C to 8°C) or deep-freeze (as cold as -70°C). https://pmc.ncbi.nlm.nih.gov/articles/PMC7869771/
[22] EAW Logistics. (2025, March 11). The future of biologic drug cold chain management. https://www.eawlogistics.com/the-future-of-biologic-drug-cold-chain-management/
[23] Airpharm. (n.d.). Logistics of innovative biologic drugs: Challenges. https://airpharm.com/en/blog/logistics-innovative-biologic-drugs-challenges/
[24] DrugPatentWatch. (2025, June 3). The dark reality of drug patent thickets: Innovation or exploitation? https://www.drugpatentwatch.com/blog/the-dark-reality-of-drug-patent-thickets-innovation-or-exploitation/
[25] DrugPatentWatch. (2025, June 3). Patent thickets and their impact on biosimilar market entry. https://www.drugpatentwatch.com/blog/the-dark-reality-of-drug-patent-thickets-innovation-or-exploitation/
[26] DrugPatentWatch. (2025, July 21). Biosimilar patent dance: Leveraging PTAB challenges for strategic advantage. https://www.drugpatentwatch.com/blog/biosimilar-patent-dance-leveraging-ptab-challenges-for-strategic-advantage/
[27] Sandoz Inc. v. Amgen Inc., 582 U.S. 1 (2017).
[29] FDA. (n.d.). Biosimilar development regulatory considerations. https://www.fda.gov/media/172197/download
[30] PMC/NCBI. (n.d.). Global harmonization of biosimilar development by overcoming regulatory divergence. https://pmc.ncbi.nlm.nih.gov/articles/PMC11880096/
[31] FDA. (n.d.). Updated FDA labeling recommendations for biosimilar and interchangeable biosimilar products. https://www.fda.gov/drugs/our-perspective/updated-fda-labeling-recommendations-biosimilar-and-interchangeable-biosimilar-products
[32] Goodwin Law. (2024, July 25). FDA issues draft guidance on demonstrating biosimilar interchangeability. https://www.goodwinlaw.com/en/insights/blogs/2024/07/fda-issues-draft-guidance-on-demonstrating-biosimilar-interchangeability
[33] The Rheumatologist. (2025, June 18). Biosimilar update: 2025 brings more FDA approvals and interchangeability. https://www.the-rheumatologist.org/article/biosimilar-update-2025-brings-more-fda-approvals-interchangeability/
[34] IQVIA. (2020, January). Why is forecasting biosimilar impact so difficult? https://www.iqvia.com/blogs/2020/01/why-is-forecasting-biosimilar-impact-so-difficult
[35] Mercalis. (n.d.). Biosimilars commercialization: Lessons learned from adalimumab and four necessary approaches. https://www.mercalis.com/system/uploads/fae/file/asset/328/Biosimilars_Commercialization.pdf
[36] Innovative RX Strategies. (2024, July 11). Four challenges impacting biosimilar savings. https://innovativerxstrategies.com/4-challenges-biosimilar-savings/
[37] AJMC. (n.d.). The economic impact of biosimilars. https://www.ajmc.com/view/the-economic-impact-of-biosimilars
[38] NORC at the University of Chicago. (2023, September). Biosimilar playbook – supply chain incentives: Infliximab. https://drugpricing.norc.org/content/dam/rx-supply/pdfs/Biosimilars%20Playbook_September%202023.pdf
[39] Grand View Research. (n.d.). Global Humira market analysis. https://www.grandviewresearch.com/industry-analysis/humira-market-report
[40] Rule Ltd. (n.d.). China dilemma: Supplier diversification strategy. https://ruleltd.com/china-dilemma-supplier-diversification-strategy/
[41] SDCExec. (2025, January 22). Strategies for mitigating supply chain risks in life sciences. https://www.sdcexec.com/transportation/cold-chain/article/22930818/labviva-strategies-for-mitigating-supply-chain-risks-in-life-sciences
[42] Duke Health Policy. (2024, November). Building a resilient and secure pharmaceutical supply chain. https://healthpolicy.duke.edu/sites/default/files/2024-11/Building%20a%20Resilient%20and%20Secure%20Pharmaceutical%20Supply%20Chain.pdf
[43] BSI Group. (n.d.). Diversify your supply chain in eleven steps. https://www.bsigroup.com/en-GB/insights-and-media/insights/blogs/diversify-your-supply-chain-in-eleven-steps/
[44] PharmaOffer. (n.d.). What are CMOs and CDMOs? https://pharmaoffer.com/blog/what-are-cmos-and-cdmos/
[45] ResearchGate. (n.d.). Optimizing pharmaceutical supply chain management through AI-driven predictive analytics: A conceptual framework. https://www.researchgate.net/publication/385696817_Optimizing_pharmaceutical_supply_chain_management_through_AI-driven_predictive_analytics_A_conceptual_framework
[46] Synapse Patsnap. (n.d.). What role does AI play in biosimilar drug development? https://synapse.patsnap.com/article/what-role-does-ai-play-in-biosimilar-drug-development
[47] ZS Associates. (n.d.). Life sciences digital supply chain transformation. https://www.zs.com/insights/life-sciences-digital-supply-chain-transformation
[48] ResearchGate. (2025, June 25). Blockchain integration for transparent and secure pharmaceutical supply chains. https://www.researchgate.net/publication/392963867_BLOCKCHAIN_INTEGRATION_FOR_TRANSPARENT_AND_SECURE_PHARMACEUTICAL_SUPPLY_CHAINS
[49] AIMultiple. (n.d.). Top 20 blockchain in supply chain case studies. https://research.aimultiple.com/blockchain-in-supply-chain-case-study/
[51] BSI Group. (n.d.). An ethical approach to a sustainable supply chain. https://www.bsigroup.com/en-GB/insights-and-media/insights/blogs/an-ethical-approach-a-sustainable-supply-chain/
[52] PSCI. (n.d.). The principles. https://pscinitiative.org/principles
